Given the sustained evolution in the area of GLP‐1 drug development and excellent safety profile, as well as the plethora of metabolic benefits, clinical approval for use in diseases beyond diabetes and obesity is very much conceivable. This evidence concerns the gene GCG and obesity due to melanocortin 4 receptor deficiency.